Our top pick for
Medallia Inc is a software-application business based in the US. Medallia shares (MDLA) are listed on the NYSE and all prices are listed in US Dollars. Medallia employs 2,037 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$33.95|
|52-week range||$23.58 - $48.28|
|50-day moving average||$33.86|
|200-day moving average||$31.26|
|Wall St. target price||$34.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.27|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-06)||N/A|
|1 month (2021-09-13)||N/A|
|3 months (2021-07-16)||10.44%|
|6 months (2021-04-16)||14.00%|
|1 year (2020-10-16)||8.88%|
|2 years (2019-10-17)||20.01%|
|3 years (2018-10-13)||N/A|
|5 years (2016-10-13)||N/A|
Valuing Medallia stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Medallia's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Medallia's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 84.825. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Medallia's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Revenue TTM||$524.5 million|
|Gross profit TTM||$306.5 million|
|Return on assets TTM||-8.65%|
|Return on equity TTM||-49.4%|
|Market capitalisation||$5.5 billion|
TTM: trailing 12 months
There are currently 9.7 million Medallia shares held short by investors – that's known as Medallia's "short interest". This figure is 14.9% up from 8.4 million last month.
There are a few different ways that this level of interest in shorting Medallia shares can be evaluated.
Medallia's "short interest ratio" (SIR) is the quantity of Medallia shares currently shorted divided by the average quantity of Medallia shares traded daily (recently around 3.6 million). Medallia's SIR currently stands at 2.7. In other words for every 100,000 Medallia shares traded daily on the market, roughly 2700 shares are currently held short.
However Medallia's short interest can also be evaluated against the total number of Medallia shares, or, against the total number of tradable Medallia shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Medallia's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Medallia shares in existence, roughly 60 shares are currently held short) or 0.0857% of the tradable shares (for every 100,000 tradable Medallia shares, roughly 86 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Medallia.
Find out more about how you can short Medallia stock.
We're not expecting Medallia to pay a dividend over the next 12 months.
Over the last 12 months, Medallia's shares have ranged in value from as little as $23.58 up to $48.28. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Medallia's is 1.4517. This would suggest that Medallia's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Medallia, Inc. provides an enterprise Software-as-a-Service platform in North America, Europe, the Middle East, Africa, and internationally. The company's platform utilizes deep learning-based artificial intelligence technology to analyze structured and unstructured data from signal fields in human, digital, and Internet of Things interactions. It offers suite of customer engagement products, such as engagement messaging, and CX profiles and journeys; contact center, including speech analytics, coaching and performance management, and quality assurance; digital products, consisting of digital experience and analytics; employee experience, comprising of employee pulse and journeys, employee ideation, and digital employee experience; and insights products, such as video and benchmarking. The company's product portfolio, comprises of Crowdicity that engages employees in sharing their ideas and observations about process, tools, and employee and customer experience enchancements in the context of existing workflows and collaboration tools; Decibel, a digital session recording and analysis platform; LivingLens, a video feedback platform; Stella Connect, a customer feedback and quality management platform that helps customer support teams analyze and improve performance in real time; Sense360, a consumer insights platform; Voci, a real-time speech to text platform; and Zingle, a multi-channel mobile messaging and customer engagement solution. In addition, it offers professional services, which include managed, implementation, and other services. The company serves retail, technology, manufacturing, financial services, insurance, and hospitality industries.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.